替莫唑胺治疗降低真核起始因子表达——eIFs在胶质瘤治疗中的潜在新意义
研究在22例胶质瘤患者来源的异种移植瘤(GBM PDX)中评估真核起始因子(eIFs)的蛋白表达与调控,发现替莫唑胺(TMZ)治疗可降低多种eIFs表达,且独立于PI3K/AKT/mTOR通路;该效应在TMZ耐药PDX中不存在,瑞戈非尼联合TMZ可重建eIF/AKT/mTOR轴。
要点
- TMZ治疗降低多种eIFs表达,且不依赖PI3K/AKT/mTOR通路。
- TMZ耐药PDX中未观察到TMZ对eIFs表达的降低效应。
- 瑞戈非尼联合TMZ可重建eIF/AKT/mTOR轴。
核心结论
- 研究为化疗对胶质瘤eIF调控的影响提供了新见解,并提示eIFs是未来改善胶质瘤治疗研究的候选靶点。
研究设计与样本
- 研究在22例胶质瘤患者来源的异种移植瘤(GBM PDX)中评估eIF蛋白表达与调控,并分析GBM PDX的突变谱。
主要发现
- 替莫唑胺(TMZ)治疗后多种eIFs表达降低,且独立于磷脂酰肌醇3-激酶(PI3K)/AKT/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路。
- TMZ耐药PDX中未出现TMZ治疗对eIFs表达的降低效应。
- 瑞戈非尼联合TMZ治疗可重建eIF/AKT/mTOR轴。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since glioma therapy is currently still limited until today, new treatment options for this heterogeneous group of tumours are of great interest. Eukaryotic initiation factors (eIFs) are altered in various cancer entities, including gliomas. The purpose of our study was to evaluate the potential of eIFs as novel targets in glioma treatment. METHODS: We evaluated eIF protein expression and regulation in 22 glioblastoma patient-derived xenografts (GBM PDX) after treatment with established cytostatics and with regards to mutation profile analyses of GBM PDX. RESULTS: We observed decreased expression of several eIFs upon temozolomide (TMZ) treatment independent from the phosphatidylinositol 3-kinase (PI3K)/ AKT/ mammalian target of the rapamycin (mTOR) signalling pathway. These effects of TMZ treatment were not present in TMZ-resistant PDX. Combination therapy of regorafenib and TMZ re- established the eIF/AKT/mTOR axis. CONCLUSION: Our study provides novel insights into chemotherapeutic effects on eIF regulation in gliomas and suggests that eIFs are interesting candidates for future research to improve glioma therapy.
引用
- Krassnig S, Leber SL, Orthmann A, et al. Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy. J Neurooncol. 2023. PMID: 37907716. doi:10.1007/s11060-023-04451-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。